CDSCO Flags 191 Drug Samples for Quality Failures in August 2

The Central Drugs Standard Control Organisation (CDSCO) has reported quality-related deficiencies in 191 drug and other pharmaceutical product samples tested during August 2026. The findings were compiled from reports submitted by state drug-testing laboratories as part of India's continuing regulatory surveillance of medicines.

The products identified in the alert cover a wide range of therapeutic and healthcare categories, including antibiotics, antidiabetic medicines, antihypertensives, analgesics, gastrointestinal preparations, injections, vitamin products, veterinary medicines and other healthcare items. The reported deficiencies varied considerably depending on the product and the applicable quality requirements.

Among the parameters in which samples were found to be non-compliant were assay, dissolution, disintegration, identification, sterility, bacterial endotoxins, uniformity of weight and conformity with the declared formulation. Some products were additionally reported as misbranded or otherwise failing requirements under the Drugs and Cosmetics Act and Rules.

The August findings included failures involving commonly used medicines such as paracetamol, cefpodoxime, levetiracetam, montelukast combinations and other formulations. The list also included an injectable product for which the reported result concerned assay requirements.

CDSCO publishes such alerts on the basis of findings received from central and state drug-testing laboratories. A product classified as Not of Standard Quality (NSQ) does not meet one or more prescribed standards applicable to that product.

The latest alert illustrates the continuing role of laboratory testing and regulatory surveillance in identifying medicines that do not comply with established quality specifications after they have entered the pharmaceutical supply chain. 

25-09-2026